In general, the best treatment outcomes were achieved when Vγ9Vδ2 cells were expanded ex vivo prior to infusion, when γδ T cell infusion was performed at the same time as tumor cell implantation, or at early timepoints such as once tumors were first palpable (<100 mm3 volume), and when the repeated administration of pAg or N-BP drugs plus cytokine (typically IL-2) was implemented. Here, IL2 is linked to neoplasm.